Cargando…
Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427024/ https://www.ncbi.nlm.nih.gov/pubmed/35542996 http://dx.doi.org/10.14283/jpad.2022.25 |
| _version_ | 1785090161619501056 |
|---|---|
| author | Cummings, J. |
| author_facet | Cummings, J. |
| author_sort | Cummings, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10427024 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104270242023-08-15 Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials Cummings, J. J Prev Alzheimers Dis Article 2022 /pmc/articles/PMC10427024/ /pubmed/35542996 http://dx.doi.org/10.14283/jpad.2022.25 Text en https://creativecommons.org/licenses/by/4.0/Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
| spellingShingle | Article Cummings, J. Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials |
| title | Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials |
| title_full | Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials |
| title_fullStr | Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials |
| title_full_unstemmed | Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials |
| title_short | Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials |
| title_sort | public policy should foster alzheimer’s treatment availability: comment on the draft us medicare decision to limit payment for aducanumab (aduhelm(™)) to patients participating in clinical trials |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427024/ https://www.ncbi.nlm.nih.gov/pubmed/35542996 http://dx.doi.org/10.14283/jpad.2022.25 |
| work_keys_str_mv | AT cummingsj publicpolicyshouldfosteralzheimerstreatmentavailabilitycommentonthedraftusmedicaredecisiontolimitpaymentforaducanumabaduhelmtopatientsparticipatinginclinicaltrials |